New GARDASIL data against Human Papillomavirus presented at EUROGIN conference

, Comments 0 comments

A real-world study evaluating the safety of GARDASIL A Human Papillomavirus Quadrivalent Recombinant Vaccine among 189,629 females in California found no serious adverse events related to vaccination, no safety signals for any health event resulting in an emergency room visit or hospitalization and no safety signals associated with pre-specified ...

0 Comments To This Article